In terms of sex, patients with RAC2 missense-mutant cancer (female, 50%; male, 50%), RAC2 splicing-mutant cancer (female, 37.5%; male, 62.5%), and RAC2 nonmutant cancer (female,52.23%; male,47.77%) were statistically different; however, because of the small number of cases, the reliability of the results cannot be fully confirmed. This evidence concerns the gene RAC2 and cancer.